184 related articles for article (PubMed ID: 16483188)
1. A human cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM overexpressing tumor cells.
Schanzer JM; Baeuerle PA; Dreier T; Kufer P
Cancer Immun; 2006 Feb; 6():4. PubMed ID: 16483188
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of a dual cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM expressing tumor cells.
Schanzer JM; Fichtner I; Baeuerle PA; Kufer P
J Immunother; 2006; 29(5):477-88. PubMed ID: 16971804
[TBL] [Abstract][Full Text] [Related]
3. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
4. Targeting of IL-2 and GM-CSF immunocytokines to a tumor vaccine leads to increased anti-tumor activity.
Fournier P; Aigner M; Schirrmacher V
Int J Oncol; 2011 Jun; 38(6):1719-29. PubMed ID: 21424118
[TBL] [Abstract][Full Text] [Related]
5. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
Stagg J; Wu JH; Bouganim N; Galipeau J
Cancer Res; 2004 Dec; 64(24):8795-9. PubMed ID: 15604233
[TBL] [Abstract][Full Text] [Related]
6. Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity.
Dela Cruz JS; Trinh KR; Morrison SL; Penichet ML
J Immunol; 2000 Nov; 165(9):5112-21. PubMed ID: 11046042
[TBL] [Abstract][Full Text] [Related]
7. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis.
Kaspar M; Trachsel E; Neri D
Cancer Res; 2007 May; 67(10):4940-8. PubMed ID: 17510424
[TBL] [Abstract][Full Text] [Related]
8. Construction and characterization of a chimeric fusion protein consisting of an anti-idiotype antibody mimicking a breast cancer-associated antigen and the cytokine GM-CSF.
Tripathi PK; Qin H; Bhattacharya-Chatterjee M; Ceriani RL; Foon KA; Chatterjee SK
Hybridoma; 1999 Apr; 18(2):193-202. PubMed ID: 10380019
[TBL] [Abstract][Full Text] [Related]
9. Targeting of interleukin-2 to human MK-1-expressing carcinoma by fusion with a single-chain Fv of anti-MK-1 antibody.
Matsumoto H; Liao S; Arakawa F; Ueno A; Abe H; Awasthi A; Kuroki M; Kuroki M
Anticancer Res; 2002; 22(4):2001-7. PubMed ID: 12174877
[TBL] [Abstract][Full Text] [Related]
10. Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony- stimulating factor induced a tumor-specific cellular immune response.
Ullenhag GJ; Frödin JE; Mosolits S; Kiaii S; Hassan M; Bonnet MC; Moingeon P; Mellstedt H; Rabbani H
Clin Cancer Res; 2003 Jul; 9(7):2447-56. PubMed ID: 12855617
[TBL] [Abstract][Full Text] [Related]
11. Construction, expression, and characterization of anticarcinoma sFv fused to IL-2 or GM-CSF.
Zhao L; Rai SK; Grosmaire LS; Ledbetter JA; Fell HP
J Hematother Stem Cell Res; 1999 Aug; 8(4):393-9. PubMed ID: 10634177
[TBL] [Abstract][Full Text] [Related]
12. Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an EP-CAM-/CD3-bispecific antibody.
Wimberger P; Xiang W; Mayr D; Diebold J; Dreier T; Baeuerle PA; Kimmig R
Int J Cancer; 2003 Jun; 105(2):241-8. PubMed ID: 12673686
[TBL] [Abstract][Full Text] [Related]
13. A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug.
de Graaf M; Boven E; Oosterhoff D; van der Meulen-Muileman IH; Huls GA; Gerritsen WR; Haisma HJ; Pinedo HM
Br J Cancer; 2002 Mar; 86(5):811-8. PubMed ID: 11875747
[TBL] [Abstract][Full Text] [Related]
14. The human ortholog of granulocyte macrophage colony-stimulating factor and interleukin-2 fusion protein induces potent ex vivo natural killer cell activation and maturation.
Penafuerte C; Bautista-Lopez N; Boulassel MR; Routy JP; Galipeau J
Cancer Res; 2009 Dec; 69(23):9020-8. PubMed ID: 19920194
[TBL] [Abstract][Full Text] [Related]
15. Targeting human Ep-CAM in transgenic mice by anti-idiotype and antigen based vaccines.
Mosolits S; Campbell F; Litvinov SV; Fagerberg J; Crowe JS; Mellstedt H; Ellis JH
Int J Cancer; 2004 Nov; 112(4):669-77. PubMed ID: 15382049
[TBL] [Abstract][Full Text] [Related]
16. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.
Brischwein K; Parr L; Pflanz S; Volkland J; Lumsden J; Klinger M; Locher M; Hammond SA; Kiener P; Kufer P; Schlereth B; Baeuerle PA
J Immunother; 2007; 30(8):798-807. PubMed ID: 18049331
[TBL] [Abstract][Full Text] [Related]
17. Fusion cytokine IL-2-GMCSF enhances anticancer immune responses through promoting cell-cell interactions.
Wen Q; Xiong W; He J; Zhang S; Du X; Liu S; Wang J; Zhou M; Ma L
J Transl Med; 2016 Feb; 14():41. PubMed ID: 26850448
[TBL] [Abstract][Full Text] [Related]
18. Antigens and cytokine genes in antitumor vaccines: the importance of the temporal delivery sequence in antitumor signals.
Herrero MJ; Botella R; Dasí F; Algás R; Sánchez M; Aliño SF
Ann N Y Acad Sci; 2006 Dec; 1091():412-24. PubMed ID: 17341632
[TBL] [Abstract][Full Text] [Related]
19. Sequential administration of GM-CSF and IL-2 surface-modified MB49 cells vaccines against the metastatic bladder cancer.
Shi X; Zhang X; Li J; Guo F; Hu Z; Jing Y; Bai L; Chen S; Wan P; Wang F; Gao J; Tan W
Urol Oncol; 2013 Aug; 31(6):883-93. PubMed ID: 21924648
[TBL] [Abstract][Full Text] [Related]
20. Antitumor efficacy induced by human ovarian cancer cells secreting IL-21 alone or combination with GM-CSF cytokines in nude mice model.
Dou J; Wang Y; Wang J; Zhao F; Li Y; Cao M; Hu W; Hu K; He XF; Chu L; Jiang C; Gu N
Immunobiology; 2009; 214(6):483-92. PubMed ID: 19389515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
